For more than a decade, research teams have explored technologies with the capacity to regenerate damaged heart tissue as a way to restore heart function with little progress. But in the last three years – armed with enabling technologies that include advances in stem cell collection, control and proliferation, recombinant protein manufacturing, and tissue engineering – a number of companies have achieved outcomes in the clinical that demonstrate restored cardiac function in patients with diseased hearts and pave the way for a new generation of treatment tools in cardiac medicine.
More than two dozen companies are currently shepherding cell-based cardiac therapy products through various stages of development and clinical validation. Several have received FDA Orphan Status or Fast Track designation. As milestones are achieved, the interest of major pharma and biotech companies is increasing, setting the stage for a spike in alliance and investment activity that will help propel the segment toward successful product and therapy commercialization.
These developments are examined in a new and comprehensive report – Branded Cellular Therapies in Cardiac Medicine: Platforms, Players and Prospects. More information is available at www.applieddata.org .
About Applied Data Applied Data Research is a healthcare therapeutics consulting firm focused on medical market strategies, product commercialization, venture development, and market research. We assist medical market participants in achieving their business objectives through the creation of detailed business development strategies, product commercialization programs, and comprehensive market and technology research and analysis.
Contact:
Greg Stone Voice: 603-595-6225 Fax: 603-804-0466 www.applieddata.org
Source: Applied Data Research
